Published in Indian J Pharm Sci on January 04, 2010
Targeting anti-HIV drugs to the CNS. Expert Opin Drug Deliv (2009) 1.05
Current approaches to enhance CNS delivery of drugs across the brain barriers. Int J Nanomedicine (2014) 1.02
Transferrin receptor on endothelium of brain capillaries. Nature (1984) 3.37
Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev (2001) 3.01
Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery (1998) 2.99
Cell-penetrating peptides. Trends Pharmacol Sci (2000) 2.42
Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci (2000) 2.01
Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet (2001) 1.96
Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci U S A (1996) 1.91
CSF drains directly from the subarachnoid space into nasal lymphatics in the rat. Anatomy, histology and immunological significance. Neuropathol Appl Neurobiol (1993) 1.85
Transporting therapeutics across the blood-brain barrier. Mol Med Today (1996) 1.82
Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: a comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers. Neurosurgery (1998) 1.72
Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res (1995) 1.68
Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res (1995) 1.65
Recent advances in blood-brain barrier transport. Annu Rev Pharmacol Toxicol (1988) 1.62
Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci (2002) 1.43
Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport. J Biol Chem (1987) 1.42
P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res (2003) 1.34
Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey. J Comp Neurol (1986) 1.29
Blood-brain barrier penetration and in vivo activity of an NGF conjugate. Science (1993) 1.25
Delivery across the blood-brain barrier of antisense directed against amyloid beta: reversal of learning and memory deficits in mice overexpressing amyloid precursor protein. J Pharmacol Exp Ther (2001) 1.19
Transport of molecules from nose to brain: transneuronal anterograde and retrograde labeling in the rat olfactory system by wheat germ agglutinin-horseradish peroxidase applied to the nasal epithelium. Brain Res Bull (1985) 1.13
Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines. J Control Release (2003) 1.13
Protection against ischemic brain injury by protein therapeutics. Proc Natl Acad Sci U S A (2002) 1.11
Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo. Proc Natl Acad Sci U S A (1995) 1.07
Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. J Control Release (2005) 1.03
Ultrasound-induced mild hyperthermia as a novel approach to increase drug uptake in brain microvessel endothelial cells. Pharm Res (2002) 1.00
Endocytic and exocytic pathways of the neuronal secretory process and trans-synaptic transfer of wheat germ agglutinin-horseradish peroxidase in vivo. J Comp Neurol (1985) 1.00
Direct drug transport from the rat nasal cavity to the cerebrospinal fluid: the relation to the dissociation of the drug. J Pharm Pharmacol (1994) 0.99
Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors. J Neurosurg (1994) 0.96
Transneuronal transport of peroxidase-conjugated wheat germ agglutinin (WGA-HRP) from the olfactory epithelium to the brain of the adult rat. Exp Brain Res (1986) 0.94
Biotin delivery to brain with a covalent conjugate of avidin and a monoclonal antibody to the transferrin receptor. J Pharmacol Exp Ther (1992) 0.91
A strategy for delivering peptides into the central nervous system by sequential metabolism. Science (1992) 0.91
Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicol Lett (2002) 0.91
Nasal route for direct delivery of solutes to the central nervous system: fact or fiction? J Drug Target (1998) 0.91
Brain-targeted delivery of a leucine-enkephalin analogue by retrometabolic design. J Med Chem (1996) 0.90
Health risks associated with inhaled nasal toxicants. Crit Rev Toxicol (2001) 0.90
Optimizing drug delivery to brain tumors. Cancer Treat Rev (1987) 0.90
Dopamine cell replacement: Parkinson's disease. Annu Rev Neurosci (1990) 0.90
Direct drug transport from the rat nasal cavity to the cerebrospinal fluid: the relation to the molecular weight of drugs. J Pharm Pharmacol (1995) 0.89
Site-specific, sustained release of drugs to the brain. Science (1981) 0.89
Drug delivery to the central nervous system: general principles and relevance to therapy for infections of the central nervous system. Rev Infect Dis (1990) 0.86
Peptidases, peptides, and the mammalian blood-brain barrier. J Neurochem (1993) 0.86
Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate of avidin and a monoclonal antibody to the transferrin receptor. Drug Metab Dispos (1994) 0.86
Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate on the permeability of zidovudine and lamivudine across the in vitro blood-brain barrier. Int J Pharm (2006) 0.84
DAB389EGF fusion protein therapy of refractory glioblastoma multiforme. Curr Pharm Biotechnol (2003) 0.82
In vitro and in vivo transport of zidovudine (AZT) across the blood-brain barrier and the effect of transport inhibitors. Pharm Res (1994) 0.82
Beta-endorphin chimeric peptides: transport through the blood-brain barrier in vivo and cleavage of disulfide linkage by brain. Endocrinology (1990) 0.82
Comparison of intravenous versus intracarotid therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea in a rat brain tumor model. Cancer Res (1985) 0.81
Nerve-cell grafting in Parkinson's disease. J Neurosurg (1988) 0.81
Blood-brain barrier permeability during hyperthermia. Prog Brain Res (1998) 0.80
Drug targeting via retrometabolic approaches. Pharmacol Ther (1998) 0.80
Effects of nonionic detergents on P-glycoprotein drug binding and reversal of multidrug resistance. Cancer Res (1993) 0.80
Use of implantable pumps for central nervous system drug infusions to treat neurological disease. Neurosurgery (1988) 0.80
New directions in the delivery of drugs and other substances to the central nervous system. Adv Pharmacol (1991) 0.80
Selective blood-tumor barrier disruption by leukotrienes. J Neurosurg (1992) 0.79
Biotechnology, the brain and the future. Trends Biotechnol (2005) 0.79
Effects of drugs on blood-brain barrier permeability in rats chronically intoxicated by ethanol. Ann Ist Super Sanita (1990) 0.78
Protective effects of neurotrophin-4/5 and transforming growth factor-alpha on striatal neuronal phenotypic degeneration after excitotoxic lesioning with quinolinic acid. Neuroscience (1997) 0.78
Cytochemical and stereological analysis of rat cortical astrocytes during development in primary culture. Effect of prenatal exposure to ethanol. Int J Dev Biol (1992) 0.78
Effect of alcohols on the permeability of blood-brain barrier. Pharmacol Res Commun (1985) 0.78
The use of nonneuronal cells for gene delivery. Neurobiol Dis (1997) 0.77
Synthesis and evaluation of a redox chemical delivery system for brain-enhanced dopamine containing an activated carbamate-type ester. J Drug Target (1994) 0.76
The brain and the lymphatic system (I). Lymphology (1996) 0.76
A quantitative structure-activity relationship study on a novel class of calcium-entry blockers: 1-[(4-(aminoalkoxy)phenyl)sulphonyl]indolizines. Eur J Med Chem (2003) 1.65
Reverse-phase, high performance liquid chromatographic method for the determination of tolterodine tartrate in routine quality control samples. PDA J Pharm Sci Technol (2010) 0.88
Design and development of integrase inhibitors as anti-HIV agents. Curr Med Chem (2003) 0.78
Liquid membrane phenomenon in the actions of digitalis. Indian J Biochem Biophys (1991) 0.75
Liquid membrane phenomenon in the biological actions of gonadal steroid hormones. Indian J Biochem Biophys (1988) 0.75
Role of liquid membrane phenomenon in the biological actions of prostaglandins: studies on prostaglandin E1 and prostaglandin F2 alpha. Indian J Biochem Biophys (1989) 0.75
Role of surface activity in the biological actions of ranitidine and famotidine. Colloids Surf B Biointerfaces (2004) 0.75
Liquid membrane phenomenon in the biological actions of benzodiazepines. Indian J Biochem Biophys (1989) 0.75
A QSAR study on renin inhibitors. Drug Des Deliv (1989) 0.75